Ash and Noom Partner to Power the Future of Proactive Health

Ash and Noom Partner to Power the Future of Proactive Health

The world of health and longevity is experiencing a pivotal shift, moving from reactive treatment to proactive prevention. Ash is proud to announce the expansion of our partnership with Noom to power the health testing infrastructure for their groundbreaking Proactive Health Microdose GLP-1Rx Program. This collaboration anchors healthy aging in clinically rigorous biomarker data and the science of healthy habits, alongside Ash as the essential at-home health testing infrastructure partner for the future of longevity.

Bridging the Digital and Physical Divide

Noom's innovative program combines three critical pillars for lasting transformation: personalized microdoses of GLP-1 medication, regular at-home biomarker testing powered by Ash, and Noom’s digital healthy habits platform.

The goal is to help millions improve the biomarkers most linked to future disease. Why is this so crucial? Because for most Americans, suboptimal health today leads to a higher risk of chronic disease tomorrow. One study found that only one in eight adults meet the criteria for optimal metabolic health. By intervening sooner, Noom can get in front of chronic disease before metabolic disorder takes root.

Ash: The Foundation for Clinically Rigorous Scale

Ash delivers the necessary infrastructure for consumer platforms that demand clinically rigorous data, operational scale, and seamless integration.

• Frictionless and Rigorous Infrastructure: At-home health testing only works at scale when the underlying infrastructure is frictionless and clinically rigorous. Ash manages the logistics, device integration, and data integrity behind the scenes.
• Best-in-Class Collection: The Ash platform is device agnostic, allowing Noom to integrate the Tasso+ device into its Noom Biomarkers test kit. This virtually painless, FDA-cleared blood lancet collects whole wet blood samples, which is ideal for patients uncomfortable with traditional lancets or needles. User experience data shows that over 95% of patients prefer Tasso over legacy methods, and more than 97% are willing to use it again.
• Actionable Insights: The foundational biomarkers—including HbA1c, metabolic panels, and kidney function markers—move the needle on long-term healthspan. The Noom Biomarkers test kit, delivered every four months, tracks an advanced set of 17 biomarkers. These biomarkers track metabolic, cardiovascular, and hormonal health, in addition to measuring inflammation and key nutrients over time.

A Vision for Accessible Longevity

The partnership is a powerful demonstration of the convergence of always-on behavior support, convenient diagnostics, and accessible care.

Ash CPO, Kyle Waters, on the collaboration:

“The future of longevity depends on seamlessly bridging the digital patient experience with best-in-class physical diagnostic tools. At-home health testing only works at scale when the underlying infrastructure is frictionless and clinically rigorous. Ash manages the logistics, device integration, and data integrity behind the scenes so partners like Noom can focus on translating biomarker data into meaningful health change.”

‍

As Noom’s Chief Product Officer, Aaron Severs, noted, this model allows members to see their progress and adjust their plan as their needs evolve, making it "health you can see, wellbeing you can feel".

The core challenge of lasting health is maintenance; most people eventually stop taking a GLP-1, with estimates reaching as high as 92%. That's why pairing medication with Noom's habit-building platform is essential—it creates the "bridge medicine" that forges new positive habits and drives better, sustained outcomes.

The Proactive Health Microdose GLP-1Rx Program is now available to eligible Noom members. The collaboration between Ash and Noom ensures that this new model of proactive health is built on a foundation of reliability, clinical integrity, and unmatched patient experience.

You can read the press release here. If you’d like to talk about how Ash can support your patient population, we’d love to chat. 

‍